Xcorporeal Competitors

Xcorporeal (OTCMKTS:XCRP) and Medtronic (NYSE:MDT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Profitability

This table compares Xcorporeal and Medtronic's net margins, return on equity and return on assets.

Insider & Institutional Ownership

79.2% of Medtronic shares are held by institutional investors. 0.5% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Xcorporeal has a beta of 3.62, indicating that its share price is 262% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Xcorporeal and Medtronic, as provided by MarketBeat.com.

Medtronic has a consensus price target of $124.2692, suggesting a potential upside of 0.30%. Given Medtronic's higher possible upside, analysts plainly believe Medtronic is more favorable than Xcorporeal.

Valuation & Earnings

This table compares Xcorporeal and Medtronic's gross revenue, earnings per share and valuation.

Medtronic has higher revenue and earnings than Xcorporeal.

Summary

Medtronic beats Xcorporeal on 9 of the 10 factors compared between the two stocks.

Xcorporeal (OTCMKTS:XCRP) and Sonova (OTCMKTS:SONVY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Profitability

This table compares Xcorporeal and Sonova's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Xcorporeal and Sonova, as reported by MarketBeat.com.

Institutional & Insider Ownership

1.1% of Sonova shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Xcorporeal has a beta of 3.62, meaning that its stock price is 262% more volatile than the S&P 500. Comparatively, Sonova has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Earnings and Valuation

This table compares Xcorporeal and Sonova's gross revenue, earnings per share (EPS) and valuation.

Sonova has higher revenue and earnings than Xcorporeal.

Summary

Sonova beats Xcorporeal on 3 of the 4 factors compared between the two stocks.

Xcorporeal (OTCMKTS:XCRP) and Varian Medical Systems (NYSE:VAR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends.

Institutional and Insider Ownership

87.0% of Varian Medical Systems shares are owned by institutional investors. 0.8% of Varian Medical Systems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for Xcorporeal and Varian Medical Systems, as reported by MarketBeat.com.

Varian Medical Systems has a consensus target price of $159.3571, indicating a potential downside of 10.00%. Given Varian Medical Systems' higher probable upside, analysts clearly believe Varian Medical Systems is more favorable than Xcorporeal.

Risk and Volatility

Xcorporeal has a beta of 3.62, meaning that its stock price is 262% more volatile than the S&P 500. Comparatively, Varian Medical Systems has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.

Profitability

This table compares Xcorporeal and Varian Medical Systems' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Xcorporeal and Varian Medical Systems' gross revenue, earnings per share and valuation.

Varian Medical Systems has higher revenue and earnings than Xcorporeal.

Summary

Varian Medical Systems beats Xcorporeal on 7 of the 8 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and Xcorporeal (OTCMKTS:XCRP) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Institutional & Insider Ownership

81.6% of Masimo shares are owned by institutional investors. 11.5% of Masimo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Masimo and Xcorporeal's revenue, earnings per share and valuation.

Masimo has higher revenue and earnings than Xcorporeal.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Masimo and Xcorporeal, as reported by MarketBeat.

Masimo currently has a consensus target price of $272.20, suggesting a potential upside of 13.63%. Given Masimo's higher possible upside, analysts plainly believe Masimo is more favorable than Xcorporeal.

Volatility & Risk

Masimo has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Xcorporeal has a beta of 3.62, suggesting that its stock price is 262% more volatile than the S&P 500.

Profitability

This table compares Masimo and Xcorporeal's net margins, return on equity and return on assets.

Summary

Masimo beats Xcorporeal on 8 of the 9 factors compared between the two stocks.

Getinge (OTCMKTS:GNGBY) and Xcorporeal (OTCMKTS:XCRP) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Getinge and Xcorporeal, as reported by MarketBeat.com.

Valuation & Earnings

This table compares Getinge and Xcorporeal's top-line revenue, earnings per share (EPS) and valuation.

Getinge has higher revenue and earnings than Xcorporeal.

Risk and Volatility

Getinge has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Xcorporeal has a beta of 3.62, meaning that its stock price is 262% more volatile than the S&P 500.

Profitability

This table compares Getinge and Xcorporeal's net margins, return on equity and return on assets.

Insider & Institutional Ownership

0.0% of Getinge shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Getinge beats Xcorporeal on 6 of the 7 factors compared between the two stocks.

LivaNova (NASDAQ:LIVN) and Xcorporeal (OTCMKTS:XCRP) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings.

Institutional and Insider Ownership

89.1% of LivaNova shares are held by institutional investors. 0.5% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares LivaNova and Xcorporeal's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares LivaNova and Xcorporeal's gross revenue, earnings per share (EPS) and valuation.

Xcorporeal has lower revenue, but higher earnings than LivaNova.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for LivaNova and Xcorporeal, as reported by MarketBeat.com.

LivaNova currently has a consensus target price of $69.3333, indicating a potential downside of 14.79%. Given LivaNova's higher probable upside, analysts plainly believe LivaNova is more favorable than Xcorporeal.

Risk & Volatility

LivaNova has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Xcorporeal has a beta of 3.62, meaning that its share price is 262% more volatile than the S&P 500.

Summary

LivaNova beats Xcorporeal on 7 of the 9 factors compared between the two stocks.